Northwestern Mutual Wealth Management Co. Has $15.91 Million Holdings in Medtronic PLC $MDT

Northwestern Mutual Wealth Management Co. cut its holdings in Medtronic PLC (NYSE:MDT) by 11.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 203,400 shares of the medical technology company’s stock after selling 25,563 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Medtronic were worth $15,912,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of MDT. Anfield Capital Management LLC increased its stake in Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 230 shares in the last quarter. Monetary Solutions Ltd purchased a new stake in shares of Medtronic in the fourth quarter worth approximately $27,000. Acumen Wealth Advisors LLC purchased a new position in Medtronic during the 4th quarter worth $29,000. IAG Wealth Partners LLC purchased a new stake in shares of Medtronic in the second quarter valued at about $30,000. Finally, Imprint Wealth LLC purchased a new stake in Medtronic in the 3rd quarter valued at about $31,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Performance

NYSE:MDT opened at $92.10 on Thursday. The firm has a market cap of $117.89 billion, a PE ratio of 22.69, a price-to-earnings-growth ratio of 2.15 and a beta of 0.56. Medtronic PLC has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The business has a 50 day moving average price of $86.27 and a 200-day moving average price of $85.35.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The firm had revenue of $9.76 billion for the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.89%. The company’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities research analysts predict that Medtronic PLC will post 5.96 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Friday, September 25th. Medtronic’s payout ratio is presently 70.94%.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Broad earnings beat and stronger outlook: Medtronic reported adjusted EPS of $1.45, above the $1.39 consensus, while revenue increased 13.7% year over year to $9.76 billion, exceeding estimates of $9.55 billion. Management raised fiscal 2027 organic revenue-growth guidance to 7.25%-7.75% and adjusted EPS guidance to $5.94-$6.00. Medtronic fiscal 2027 results
• Positive Sentiment: Growth was broad-based: Cardiovascular revenue rose 19.5%, neuroscience increased 10.3%, medical surgical grew 10.0% and diabetes advanced 16.9%. Analysts characterized the results as evidence of a potential growth acceleration across both established franchises and newer platforms. Medtronic beat-and-raise analysis
• Positive Sentiment: Robotics and heart-tech expansion: Medtronic committed approximately $700 million to a strategic partnership with Cornerstone Robotics, gaining distribution rights for its Sentire surgical system in select markets outside the United States. It also agreed to invest up to $80 million in Pi-Cardia to support complex TAVR procedures. These moves could broaden Medtronic’s long-term growth opportunities in minimally invasive surgery and structural heart care. Cornerstone Robotics partnership
• Positive Sentiment: Analyst support increased: RBC reaffirmed an Outperform rating and set a $118 price target. BTIG raised its target to $100 and maintained a Buy rating, while Baird lifted its target to $100. These revisions indicate improving confidence in Medtronic’s earnings trajectory. Analyst price-target revisions
• Neutral Sentiment: Some caution remains: Stifel raised its price target to $95 but kept a Hold rating, and Baird retained a Neutral rating despite its higher target. The second-quarter EPS outlook of $1.32-$1.34 is below the $1.35 consensus, suggesting investors may continue to watch execution and the sustainability of the recent growth acceleration.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on MDT shares. Wells Fargo & Company lifted their target price on Medtronic from $102.00 to $104.00 and gave the stock an “overweight” rating in a research note on Wednesday. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Rothschild & Co Redburn lowered their price target on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating on the stock in a report on Friday, June 5th. Royal Bank Of Canada reissued an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research note on Wednesday. Finally, Bank of America boosted their price target on shares of Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday. Nineteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $102.96.

Insider Activity

In related news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.27% of the stock is owned by corporate insiders.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).